Implant Innovations, Inc. ("3i") and Colbar Research & Development Ltd., of Ramat-Hasharon, Israel announced a strategic worldwide alliance in which 3i will sell and market Colbar�s collagen barrier membrane material--Ossix�. This alliance combines Colbar�s newly created technology to prepare highly purified collagen (U.S. bovine source) product with a programmed bio-durability (longevity) with 3i's expertise in dental implants and other regenerative products used in dental surgical applications.
Ossix� is a six-month resorbable collagen membrane that is used for guided bone regeneration. With superior handling characteristics as compared to existing materials and predictable clinical outcomes, it has a patented cross-linking technology that resists degradation for a full six-months, and then gradually resorbs within 8 to 10 months. Ossix� has FDA approval for U.S. distribution and is qualified for bearing the CE marking.
"Our agreement with Colbar allows us to add a cutting edge regenerative material to our portfolio of dental products. 3i's Osseotite� dental implants, Platelet Concentrate Collection System� (PCCS�), Biogran� bone grafting products, and Colbar regenerative materials are the leading technologies in their field and 3i is pleased to be able to bring them to clinicians worldwide," said Bart Doedens, president of 3i.
Italy Itzhaky, chief executive officer of Colbar Research & Development Ltd. said, "Colbar believes this strategic agreement, based on 3i's position in the world dental implant market and Colbar�s new innovative cross-linking technology, will give Ossix� a leading position in the market."
